Somatostatin analogs with improved oral bioavailability.

Area of Science:

• Medicinal Chemistry
• Endocrinology
• Peptide Synthesis

Background:

• Somatostatin analogs are crucial for regulating hormone release.
• Existing analogs face challenges with oral bioavailability and metabolic stability.
• Development of more potent and orally active somatostatin analogs is needed.

Purpose of the Study:

• To synthesize novel cyclic hexapeptide analogs of somatostatin.
• To enhance the inhibitory potencies against insulin, glucagon, and growth hormone (GH) release.
• To improve oral bioavailability and duration of action compared to native somatostatin.

Main Methods:

• Chemical synthesis of cyclic hexapeptide analogs.
• Modification of the Phe-7 residue to histidine.
• Incorporation of histidine to prevent metabolic degradation.
• Evaluation of in vitro and in vivo biological activities.

Main Results:

• Synthesized analogs exhibit 50-200 times greater inhibitory potency than somatostatin.
• Replacement of Phe-7 with histidine significantly increased oral bioavailability and duration.
• Histidine incorporation successfully overcame metabolic degradation of L-Trp containing analogs.
• An all-L-amino acid analog demonstrated oral bioavailability comparable to D-Trp analogs.

Conclusions:

• Novel cyclic hexapeptide analogs of somatostatin possess superior inhibitory properties.
• Histidine substitution is a key strategy for enhancing oral delivery and stability.
• These findings offer promising candidates for therapeutic interventions requiring somatostatin modulation.